undamentalytics Newsletter
Sign in

Pulse Biosciences, Inc. (PLSE) stock

Add to watchlist

Add holding +

NASDAQ: PLSE Nasdaq Health Care Equipment Next results ~November 5, 2026

E Fundamentals grade

Pulse Biosciences, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Pulse Biosciences, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.

Pulse Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 1 selling8 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds61 adding, 33 cuttingOf 15 active managers that changed their stake, 8 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Pulse Biosciences files

Where Pulse Biosciences stands after its latest 10-Q

Pulse Biosciences has little or no product revenue yet; it used $61m of cash in the twelve months to June 2026. The diluted share count is up 7.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our model value for Pulse Biosciences is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Where it stands out: days sales outstanding of 38 days ranks 18 of 118 health care equipment companies we cover. Where it lags: stock pay as % of revenue of 1474.4% ranks 121 of 123 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 37.2% while net income fell 17.7%: a 20pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 100.0% over the last 12 months.
  • Margins widening. Operating margin is up 446234.2 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -7007.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -5180.4% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 1474.4% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 7.4% in a year.
  • High sales multiple. The shares trade at 3040 times revenue while operating margins remain thin.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.28 against an average estimate of -$0.28: beat by 1.5%
Revenue
$0m
Share reaction
+11.9% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.29

Pulse Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.3%
  • 1 week+0.5%
  • 1 month+10.4%
  • This year+285.3%
  • 1 year+212.5%
  • 5 years+132.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.2M
Operating margin
-7007.8%
Net margin
-6755.8%
EPS (TTM, diluted)
$-1.18

Growth

Share count change
+7.4%

Cash

Free cash flow (TTM)
-$61.4M
FCF margin
-5180.4%
Stock pay % of revenue
1474.4%

Earnings

Last results
August 6, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Agreement
  4. Announcement
  5. Agreement
  6. Results
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Pulse Biosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Pulse Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.2 ~$1.1–$1.2 Left out: out of range vs price (0.02x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.1 ~$0.1–$0.4 Left out: out of range vs price (0.00x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pulse Biosciences, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$23.86$14.81$2.77$12.24$17.41$13.73$52.90
Market value$555m$414m$94m$609m$1.0bn$925m$3.6bn
+ Net debt (− = net cash)−$12m−$44m$5m−$44m−$118m−$81m−$102m
Enterprise value$542m$370m$99m$564m$899m$845m$3.5bn
Multiples
Price / sales —n/m134.3x——n/mn/m
Price / earnings ———————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $521670 and EPS of −$0.29 (range −$0.30 to −$0.28) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.11 −47% $2m +481%
Next −$1.17 −6% $6m +178%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +3.5% on 90 days ago. In the last 30 days, 1 analyst raised Pulse Biosciences, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Pulse Biosciences, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.07 Current fiscal year, 60 days ago: −$1.10 Current fiscal year, 30 days ago: −$1.11 Current fiscal year, 7 days ago: −$1.11 Current fiscal year, Now: −$1.11 −$1.11 Next fiscal year, 90 days ago: −$1.09 Next fiscal year, 60 days ago: −$1.16 Next fiscal year, 30 days ago: −$1.15 Next fiscal year, 7 days ago: −$1.17 Next fiscal year, Now: −$1.17 −$1.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.07−$1.09
60 days ago −$1.10−$1.16
30 days ago −$1.11−$1.15
7 days ago −$1.11−$1.17
Now −$1.11−$1.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.28 −$0.28 +1.5%
Mar 2026 −$0.22 −$0.24 −9.7%
Dec 2025 −$0.21 −$0.18 +14.3%
Sept 2025 −$0.31 −$0.29 +6.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026156
  2. Sep 2026156
  3. Aug 2026134
  4. Jul 202633

Counts of recommendations published by analysts covering Pulse Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.1%
of tradable shares
Days to cover
5.88
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
15%
of shares
Held by insiders
71.0%
of shares
Employees
116
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PLSE−38%−81%+342%+42%−21%+285%
Industry peers (median)−7%−37%−9%−20%−16%−15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PLSE25%25%67%42%50%82%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PLSE−67%−92%−56%−45%−49%−30%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 18, 2016: 97% from February 8, 2021 to August 30, 2022. Getting back needed a 3499% gain, reached on August 11, 2026, 1442 days after the low.

Price behaviour

52-week range
$12.66 – $55.48
From 52-week high
−4.7%
vs 50-day average
+3.5%
vs 200-day average
+67.7%
Volatility (1 year)
88%
Beta vs S&P 500
2.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±7.3%
After a week
4 up, 8 down
typical move ±10.2%
After a month
8 up, 4 down
typical move ±21.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +11.9% +0.5% +18.5% +40.5%
May 4, 2026 −10.5% +0.4% −8.4% +20.0%
February 19, 2026 −15.9% +0.5% −24.2% −13.2%
November 5, 2025 −2.1% −0.7% −6.6% −17.4%
August 12, 2025 +12.8% +1.4% +6.6% +1.5%
May 8, 2025 +2.3% +0.6% −1.2% +3.6%
March 28, 2025 +2.7% −1.4% −3.7% +13.7%
October 30, 2024 +2.3% −2.3% +5.9% +25.6%
August 12, 2024 +8.1% +1.7% +27.5% +9.5%
July 15, 2024 +3.8% +0.9% −9.5% −9.0%
May 7, 2024 −10.7% +0.1% −0.5% +88.2%
March 28, 2024 −4.9% −0.2% −9.9% −13.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Pulse Biosciences, Inc.
-$500K $0 $500K $1M $1.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: -$9K Revenue (TTM), FY23 Q4: $0 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $0 Revenue (TTM), FY24 Q3: $0 Revenue (TTM), FY24 Q4: $0 Revenue (TTM), FY25 Q1: $0 Revenue (TTM), FY25 Q2: $0 Revenue (TTM), FY25 Q3: $86K Revenue (TTM), FY25 Q4: $350K Revenue (TTM), FY26 Q1: $751K Revenue (TTM), FY26 Q2: $1.2M $1.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 -$9K
FY23 Q4 $0
FY24 Q1 $0
FY24 Q2 $0
FY24 Q3 $0
FY24 Q4 $0
FY25 Q1 $0
FY25 Q2 $0
FY25 Q3 $86K
FY25 Q4 $350K
FY26 Q1 $751K
FY26 Q2 $1.2M
Revenue growth, TTM YoY Pulse Biosciences, Inc.
-100% -50% 0% 50% 100% FY23 Q4 FY24 Q1 FY24 Q2 FY24 Q3 Revenue growth, TTM YoY, FY23 Q4: -100.0% Revenue growth, TTM YoY, FY24 Q1: -100.0% Revenue growth, TTM YoY, FY24 Q2: 100.0% Revenue growth, TTM YoY, FY24 Q3: 100.0% 100.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -100.0%
FY24 Q1 -100.0%
FY24 Q2 100.0%
FY24 Q3 100.0%
Operating margin (TTM) Pulse Biosciences, Inc.
-200000% 0% 200000% 400000% 600000% FY22 Q2 FY22 Q4 FY23 Q2 FY25 Q3 FY26 Q2 Operating margin (TTM), FY22 Q2: -2866.5% Operating margin (TTM), FY22 Q3: -4167.5% Operating margin (TTM), FY22 Q4: -8293.9% Operating margin (TTM), FY23 Q1: -19666.4% Operating margin (TTM), FY23 Q2: 517322.2% Operating margin (TTM), FY23 Q3: 442066.7% Operating margin (TTM), FY25 Q3: -91798.8% Operating margin (TTM), FY25 Q4: -21982.6% Operating margin (TTM), FY26 Q1: -10392.1% Operating margin (TTM), FY26 Q2: -7007.8% -7007.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY22 Q2 -2866.5%
FY22 Q3 -4167.5%
FY22 Q4 -8293.9%
FY23 Q1 -19666.4%
FY23 Q2 517322.2%
FY23 Q3 442066.7%
FY25 Q3 -91798.8%
FY25 Q4 -21982.6%
FY26 Q1 -10392.1%
FY26 Q2 -7007.8%
FCF margin (TTM) Pulse Biosciences, Inc.
-200000% 0% 200000% 400000% FY22 Q2 FY22 Q4 FY23 Q2 FY25 Q3 FY26 Q2 FCF margin (TTM), FY22 Q2: -2588.1% FCF margin (TTM), FY22 Q3: -3363.6% FCF margin (TTM), FY22 Q4: -6773.4% FCF margin (TTM), FY23 Q1: -14902.3% FCF margin (TTM), FY23 Q2: 383633.3% FCF margin (TTM), FY23 Q3: 381588.9% FCF margin (TTM), FY25 Q3: -56714.0% FCF margin (TTM), FY25 Q4: -15553.4% FCF margin (TTM), FY26 Q1: -7390.0% FCF margin (TTM), FY26 Q2: -5180.4% -5180.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q2 -2588.1%
FY22 Q3 -3363.6%
FY22 Q4 -6773.4%
FY23 Q1 -14902.3%
FY23 Q2 383633.3%
FY23 Q3 381588.9%
FY25 Q3 -56714.0%
FY25 Q4 -15553.4%
FY26 Q1 -7390.0%
FY26 Q2 -5180.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 1 0 0 0 1
Gross profit 0 −1 −11 0 0 −0 0
EBITDA −50 −63 −57 −43 −56 −77 −83
Operating income −50 −63 −58 −44 −56 −77 −83
Net income −50 −64 −59 −42 −54 −73 −80
Diluted EPS −$2.14 −$2.28 — — — — −$1.18
Growth (year on year)
Revenue — — −50.6% −100.0% — — —
Margins
Gross margin — −38.8% <−999% — — −54.0% 0.3%
EBITDA margin — <−999% <−999% — — <−999% <−999%
Operating margin — <−999% <−999% — — <−999% <−999%
Net margin — <−999% <−999% — — <−999% <−999%
Free-cash-flow margin — <−999% <−999% — — <−999% <−999%
Cash flow
Cash from operations −35 −54 −47 −33 −36 −54 −61
Capital spending 0 0 0 0 0 0 0
Free cash flow −36 −55 −47 −33 −36 −54 −61
Stock-based pay 10 15 5 7 14 21 17
Free cash flow after stock pay −46 −69 −53 −40 −50 −76 −79
Balance sheet
Cash 12 44 61 44 118 81 102
Total debt 0 — 66 0 0 0 0
Net debt (negative = net cash) −12 −44 5 −44 −118 −81 −102
Diluted shares 23m 28m 34m 50m 58m 67m 68m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $116m
Short-term assets $106mLonger-term assets $10m
What it owes, and who funded it · $116m
Short-term liabilities $11mLonger-term liabilities $5mShareholders' equity $100m
  • Short-term assets cover short-term liabilities $106m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $106m short-term assets against $5m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Pulse Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+7.4%
year over year
R&D spending
4378.6%
of revenue
Sales & admin spending
2629.5%
of revenue
Days sales outstanding
38 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated PLSE IMDX ICU CODX FEMY VNRX Median
Revenue, last 12 months $1m $2m $2m $721387 $2m $2m $99m
Revenue growth, last 12 months 100.0% −60.8% 123.6% −28.1% 21.9% 86.3% 9.2%
Revenue growth, 3-year average — 14.9% — −53.8% 24.3% 68.0% 13.5%
Revenue growth, latest quarter 100.0% −53.9% 82.0% 2.0% −18.9% −2.0% 10.2%
Gross margin 0.3% 48.3% 92.6% 43.5% 60.9% — 61.2%
Operating margin <−999% <−999% −816.6% <−999% −763.9% −790.2% −8.5%
Operating margin, 3-year average >999% <−999% — <−999% <−999% <−999% −17.9%
Net margin <−999% <−999% −795.5% <−999% −511.8% <−999% −12.0%
Cash from operations / revenue <−999% <−999% −799.4% <−999% −767.6% −795.9% −1.9%
Free-cash-flow margin <−999% <−999% — <−999% −786.0% −796.7% −3.9%
Free-cash-flow margin, 3-year average >999% <−999% — <−999% <−999% <−999% −7.0%
Stock pay / revenue >999% 150.8% 20.5% 169.9% 26.2% 38.2% 6.1%
Change in share count 7.4% 16.8% — 4.0% — 16.3% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Gross margin Profitability 0.3% 61.9% 119 of 123
Operating margin Profitability -7007.8% -8.3% 129 of 132
Net margin Profitability -6755.8% -12.0% 130 of 133
Free-cash-flow margin Cash generation -5180.4% -3.4% 125 of 128
Stock pay as % of revenue Cash generation 1474.4% 6.1% 121 of 123
Change in share count Balance sheet 7.4% 3.3% 80 of 115
Days sales outstanding Balance sheet 38 days 57 days 18 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$297M
Institutions reporting
105
Shares held vs prior quarter
▲ 37.9%
Positions opened / closed
19 / 10

Top buyers and sellers, Q2 2026: 61 institutions bought and 33 sold ; the biggest buyer was Price T Rowe Associates Inc (+734K shares) and the biggest seller LMR Partners LLP (−213K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $40.7M 1.5M 13.7% ▲ 9.5%
Bank Of America Corp $40.1M 1.4M 13.5% ▲ 67.0%
Vanguard Capital Management LLC $21.9M 789K 7.4% ▼ 3.3%
Portolan Capital Management, LLC $20.9M 753K 7.0% ▲ 2.7%
Price T Rowe Associates Inc $20.8M 749K 7.0% ▲ 4938.3%
Balyasny Asset Management L.P. $19.9M 718K 6.7% ▲ 170.8%
Citadel Advisors LLC $17.4M 627K 5.9% ▲ 340.7%
Geode Capital Management, LLC $14.9M 536K 5.0% ▲ 9.0%
State Street Corp $14.7M 530K 4.9% ▲ 15.9%
Massachusetts Financial Services Co $12.8M 463K 4.3% 0.0%
UBS Group AG $7.6M 276K 2.6% ▲ 711.9%
Griffin Asset Management, Inc. $6.3M 227K 2.1% ▲ 0.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pulse Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $26.8M 8 trades by 3 insiders, last 12 months Insider sales History → $2.9M 7 trades by 1 insider · 100% under pre-set plans
Net ▲ $23.9M net buying
Insider Date Trade Shares Price Value
Teplitsky Liane Rae Chief Operating Officer September 1, 2026 Buy 1,001 $49.95 $50,000
Teplitsky Liane Rae Chief Operating Officer August 31, 2026 Buy 1,024 $48.80 $49,971
Teplitsky Liane Rae Chief Operating Officer August 28, 2026 Buy 1,034 $48.35 $49,994
Teplitsky Liane Rae Chief Operating Officer August 26, 2026 Buy 1,036 $48.24 $49,977
Duggan Robert W Director May 11, 2026 Buy 660,233 $19.69 $13M
Laviolette Paul A Chief Executive Officer May 11, 2026 Buy 15,000 $19.69 $295,350
Laviolette Paul A Chief Executive Officer May 11, 2026 Buy 15,000 $19.69 $295,350
Duggan Robert W Director May 11, 2026 Buy 660,233 $19.69 $13M
Danahy Kevin Patrick Chief Commercial Officer February 18, 2026 Sell pre-set plan 5,000 $23.64 $118,200
Danahy Kevin Patrick Chief Commercial Officer February 17, 2026 Sell pre-set plan 20,000 $23.63 $472,600
Danahy Kevin Patrick Chief Commercial Officer February 13, 2026 Sell pre-set plan 20,000 $23.53 $470,600
Danahy Kevin Patrick Chief Commercial Officer February 12, 2026 Sell pre-set plan 20,000 $23.37 $467,400

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 4, 2026
  • February 19, 2026
  • November 5, 2025
  • August 12, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Pulse Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Pulse Biosciences, Inc. in brief

What does Pulse Biosciences, Inc. do?
Pulse Biosciences, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Pulse Biosciences, Inc.'s stock ticker?
Pulse Biosciences, Inc. trades under the ticker PLSE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Pulse Biosciences, Inc.'s free cash flow?
Pulse Biosciences, Inc.'s free-cash-flow margin is -5180.4% of revenue over the trailing twelve months, ranking 125 of the 128 health care equipment companies we cover.
Who are Pulse Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Bank Of America Corp and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Pulse Biosciences, Inc.'s market cap?
On November 2, 2026, Pulse Biosciences, Inc.'s market capitalisation was about $3.6B and net debt of -$102M. Market figures come from third-party market data and may be delayed.
Who are Pulse Biosciences, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Pulse Biosciences, Inc. are Insight Molecular Diagnostics Inc., Seastar Medical Holding Corp, Co-diagnostics, Inc., Femasys Inc and Volitionrx LTD. The side-by-side comparison below sets their revenue, margins and growth against Pulse Biosciences, Inc.'s.
Are insiders buying or selling Pulse Biosciences, Inc. stock?
Over the last 12 months, Pulse Biosciences, Inc.'s directors and officers reported 8 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is Pulse Biosciences, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Pulse Biosciences, Inc. announces its own schedule.